The biopharmaceutical sector is under extreme pressure to accelerate timelines and increase productivity. In silico process development constitutes an attractive option for accelerating CMC development timelines by at least 50% and can remove at least nine months from the time between discovery of a drug to its market entry, thereby improving risk-adjusted Net Present Values (NPVs) by at least 10%. This report surveys the in silico bioprocessing market for the 2022-20227 period.